View clinical trials related to Hodgkin's Disease.
Filter by:Primary Objective: To determine the safety and efficacy of Campath-1H (Alemtuzumab) in patients with relapsed and resistant classical Hodgkin's lymphoma. Secondary Objectives: 1. To determine the duration of response and time to progression after Campath-1H therapy in this patient population. 2. To determine the effect of Campath-1H on serum IL-6, IL-10, and IL-13 levels in patients with relapsed and resistant classical Hodgkin's lymphoma.